Literature DB >> 25798236

Roles of Rheb(S16H) in substantia nigra pars compacta dopaminergic neurons in vivo.

Min-Tae Jeon1, Sang Ryong Kim2.   

Abstract

Although there are ongoing intensive research efforts, no effective pharmacological therapies for Parkinson's disease (PD) have been developed thus far. However, with the development of efficient gene delivery systems, gene therapy for PD has become a focus of research and increasing evidence suggests that continuous production of neurotrophic factors play a significant role in the functional restoration of the nigrostriatal dopaminergic (DA) system. Our recent study reported that the transduction of DA neurons with ras homolog enriched in brain, which has an S16H mutation [Rheb(S16H)], protected the nigrostriatal DA projection in a neurotoxin model of PD in vivo. In addition, Rheb(S16H) expression significantly increased the levels of glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor, which contributed to the neuroprotective effects of Rheb(S16H) in DA neurons in the adult brain, indicating that the activation of the signaling pathways involved in cell survival by a specific gene delivery, such as Rheb(S16H) to adult neurons, may be a useful strategy to protect neural systems in the adult brain. In the present study, a brief overview of our recent studies is provided, which demonstrates the neuroprotective mechanisms of Rheb(S16H) on the nigrostriatal DA projection in the adult brain.

Entities:  

Keywords:  Parkinson's disease; Rheb(S16H); brain-derived neurotrophic factor; glial cell line-derived neurotrophic factor; neuroprotection

Year:  2014        PMID: 25798236      PMCID: PMC4360870          DOI: 10.3892/br.2014.397

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  33 in total

1.  AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.

Authors:  Sang Ryong Kim; Tatyana Kareva; Olga Yarygina; Nikolai Kholodilov; Robert E Burke
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Naringin protects the nigrostriatal dopaminergic projection through induction of GDNF in a neurotoxin model of Parkinson's disease.

Authors:  Eunju Leem; Jin Han Nam; Min-Tae Jeon; Won-Ho Shin; So-Yoon Won; Sang-Joon Park; Myung-Sook Choi; Byung Kwan Jin; Un Ju Jung; Sang Ryong Kim
Journal:  J Nutr Biochem       Date:  2014-04-01       Impact factor: 6.048

3.  Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons.

Authors:  D J Creedon; M G Tansey; R H Baloh; P A Osborne; P A Lampe; T J Fahrner; R O Heuckeroth; J Milbrandt; E M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 4.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

5.  Glial cell line-derived neurotrophic factor receptor-α1 expressed in striatum in trans regulates development and injury response of dopamine neurons of the substantia nigra.

Authors:  Nikolai Kholodilov; Sang Ryong Kim; Olga Yarygina; Tatyana Kareva; Jin Whan Cho; Amy Baohan; Robert E Burke
Journal:  J Neurochem       Date:  2011-01-19       Impact factor: 5.372

6.  Effects of brain-derived neurotrophic factor on neuronal structure of dopaminergic neurons in dissociated cultures of human fetal mesencephalon.

Authors:  L Studer; C Spenger; R W Seiler; A Othberg; O Lindvall; P Odin
Journal:  Exp Brain Res       Date:  1996-03       Impact factor: 1.972

7.  AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.

Authors:  Xinmiao Ren; Ting Zhang; Xiaoli Gong; Guanzheng Hu; Wei Ding; Xiaomin Wang
Journal:  Exp Neurol       Date:  2013-06-10       Impact factor: 5.330

8.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Authors:  J G Nutt; K J Burchiel; C L Comella; J Jankovic; A E Lang; E R Laws; A M Lozano; R D Penn; R K Simpson; M Stacy; G F Wooten
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

Review 9.  Treatment of Parkinson's disease with trophic factors.

Authors:  Amie L Peterson; John G Nutt
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 10.  Parkinson's disease gene therapy: success by design meets failure by efficacy.

Authors:  Raymond T Bartus; Marc S Weinberg; R Jude Samulski
Journal:  Mol Ther       Date:  2013-12-20       Impact factor: 11.454

View more
  2 in total

Review 1.  Upregulation of Neuronal Rheb(S16H) for Hippocampal Protection in the Adult Brain.

Authors:  Gyeong Joon Moon; Minsang Shin; Sang Ryong Kim
Journal:  Int J Mol Sci       Date:  2020-03-16       Impact factor: 5.923

Review 2.  Therapeutic Potential of AAV1-Rheb(S16H) Transduction against Neurodegenerative Diseases.

Authors:  Youngpyo Nam; Gyeong Joon Moon; Sang Ryong Kim
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.